SM
OCUL icon

Sabby Management’s Ocular Therapeutix OCUL Stock Holding History

Sabby Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,097
Closed -$2.1M – 201
2021
Q3 		$2.1M Buy
2,097
+539
+35% +$6.05K 0.28% 51
2021
Q2 		$2.21M Buy
1,558
+328
+27% +$4.99K 0.31% 51
2021
Q1 		$2.02M Buy
+1,230
New +$23.7K 0.39% 52

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Sabby Management's OCUL Position: Q4 2021 in Review

Sabby Management sold out of Ocular Therapeutix (OCUL) in Q4 2021, closing a stake of 142,000 shares — an estimated $1.42M sold.

Sabby Management first reported a position in OCUL in Q3 2014 and held it in 9 quarters. The position peaked at $2.1M in Q2 2015. 140 funds tracked by Wall St. Rank hold OCUL as of Q4 2021.

  • Sabby Management reported no remaining Ocular Therapeutix position as of Q4 2021 after selling out during the quarter.
  • Sabby Management sold 142,000 Ocular Therapeutix shares in Q4 2021, an estimated $1.42M.
  • Sabby Management first reported a position in Ocular Therapeutix in Q3 2014 and held it in 9 quarters.
  • Sabby Management's Ocular Therapeutix position peaked at $2.1M in Q2 2015.
  • 140 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.